IDEAYA Biosciences (IDYA) Receivables - Other (2025 - 2026)

IDEAYA Biosciences (IDYA) posted Receivables - Other of $6.6 million for Q1 2026, up 9.83% sequentially from $6.0 million in Q4 2025.

Analysis

IDEAYA Biosciences (IDYA) Receivables - Other (2025 - 2026) Analysis & Trends

IDEAYA Biosciences has reported Receivables - Other for 2 years, with the latest figure at $6.6 million in Q1 2026.

Quarterly Receivables - Other changed N/A year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (changed N/A YoY) and the FY2025 annual result came in at $6.0 million, changed N/A from the prior year.
Receivables - Other grew to $6.6 million in Q1 2026 per IDYA's latest filing, from $6.0 million in the prior quarter.
Over five years, Receivables - Other peaked at $6.6 million in Q1 2026 and troughed at $6.0 million in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	IDEAYA Biosciences	3.68 Bn	2.85 Bn	-

Historic Data

Download Data